Rimegepant

For Acute and Preventive Treatment of Migraine

Rimegepant, our lead product candidate, is an orally available, selective and potent small molecule CGRP receptor antagonist. We believe rimegepant has the potential to be a best-in-class CGRP receptor antagonist for the acute treatment and prevention of migraine with the ability to address important unmet needs.

Rimegepant Overview

Description

Click to expend Orally available, selective and potent small molecule CGRP receptor antagonist
  • Biohaven believes that this novel mechanism, in combination with the drug’s long half-life, good oral bioavailability, and high affinity for the human CGRP receptor, make rimegepant a potential best-in-class molecule for the acute treatment of migraine.